Understanding How Breast Cancers Activate and Respond to the Systemic Environment

了解乳腺癌如何激活和响应全身环境

• 批准号: 9315710
• 负责人: Sandra S McAllister
• 金额: $ 35.67万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-18 至 2018-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9315710
• 关键词: Address; Affect; Aftercare; Anatomy; Biological Models; Blood Circulation; Bone Marrow; Bone Marrow Cells; Breast Cancer Cell; Breast Cancer Patient; Breast Cancer therapy; Cancer Biology; Cancer Relapse; Categories; Cells; Clinical; Cues; Desmoplastic; Development; Diagnosis; Disease; Distant; Effectiveness; Environment; Event; Fibroblasts; Functional disorder; Growth; Growth Factor; Hematopoietic; Hematopoietic stem cells; Human; Indolent; Knowledge; Life; Malignant - descriptor; Malignant Epithelial Cell; Malignant Neoplasms; Mammary Neoplasms; Mediating; Microarray Analysis; Molecular; Neoplasm Metastasis; PTPRC gene; Patients; Play; Process; Property; Recruitment Activity; Recurrence; Recurrent disease; Role; Severity of illness; Signal Transduction; Site; Testing; Therapeutic; Time; Tissue Microarray; Treatment Protocols; Tumor Subtype; Tumor Tissue; Tumorigenicity; Up-Regulation; Woman; base; cancer subtypes; cohort; cytokine; design; experience; experimental study; granulin; insight; malignant breast neoplasm; mouse model; neoplastic cell; novel; osteopontin; pre-clinical; preclinical development; prevent; prognostic assays; relapse patients; response; subtype-specific therapies; therapy design; triple-negative invasive breast carcinoma; tumor; tumor growth; tumor heterogeneity; tumor microenvironment; tumor progression; tumorigenic

DESCRIPTION (provided by applicant): Breast cancer is the most common malignancy among women worldwide. Breast cancers are classified into different categories based on their molecular and histopathological features. While disease severity can be stratified, a profound problem is the lack of effectiveness of many of the current treatment regimens. One of the greatest challenges in breast cancer management is recurrent disease, which affects 30 percent of breast cancer patients and is usually incurable. Part of the problem is that certain tumor cells remain undetected in the body for extended periods of time before they suddenly erupt into overt, life-threatening cancers. Patients with some types of breast cancers experience recurrence within months of their original diagnosis, while other patients relapse as late as 15-20 years after treatment. It is difficult to predict whether tumor cells that have spread throughou a patient's body will remain inactive or whether they will begin to grow and, if so, what triggers their growth. We propose to address these clinical problems by using our novel experimental mouse model system that gave us important insights into breast cancer pathophysiology. We learned that some tumors that would otherwise remain dormant can respond to certain growth factors and bone marrow-derived cells that circulate throughout the body, which we collectively refer to as the systemic environment. However, tumors are not just passive recipients of circulating growth factors and cells. Instead, certain tumors actively create a systemic environment that is favorable to the growth of disseminated tumor cells that otherwise would not grow in the normal, unperturbed systemic environment. We contend that many aspects of breast cancer biology can only be explained by a detailed understanding of both activation and response to the systemic environment. We propose to build upon our fundamental observations with the following specific aims: 1. Determine which types of breast cancers are capable of establishing a tumor-supportive systemic environment and how they do so. 2. Define the properties of breast cancers that are capable of responding to a tumor-promoting systemic environment. 3. Determine whether inhibiting certain aspects of the tumor-promoting environment will prevent the growth of otherwise indolent tumors. Understanding how certain tumors activate the systemic environment should help us to design therapies to inhibit their pro-tumorigenic functions. As importantly, understanding the properties of tumor cells that respond to these systemic factors should allow us to determine whether a patient harbors these responsive cells. These mechanistic studies have the potential to pave the way for more effective breast cancer therapies.

描述（由申请人提供）：乳腺癌是全球女性中最常见的恶性肿瘤。乳腺癌根据其分子和组织病理学特征分为不同的类别。尽管疾病的严重程度可以分层，但一个深刻的问题是许多当前治疗方案缺乏有效性。乳腺癌管理中最大的挑战之一是复发性疾病，这会影响30％的乳腺癌患者，并且通常无法治愈。问题的一部分是某些肿瘤细胞 在体内未发现的长时间，然后突然爆发到明显的，威胁生命的癌症中。患有某些类型的乳腺癌的患者在最初诊断后的几个月内经历了复发，而其他患者在治疗后15至20年后复发。很难预测通过患者体内传播的肿瘤细胞是否会保持不活跃，或者它们是否会开始生长，如果是的话，是什么触发其生长。我们建议通过使用新型的实验小鼠模型系统来解决这些临床问题，该系统为我们提供了对乳腺癌病理生理学的重要见解。我们了解到，某些否则会保持休眠状态的肿瘤可以对某些生长因子和骨髓衍生的细胞反应，这些细胞在整个体内循环，我们共同称为系统环境。但是，肿瘤不仅是循环生长因子和细胞的被动接受者。取而代之的是，某些肿瘤会积极创建一个有利于散布肿瘤细胞生长的系统环境，否则在正常的，不受干扰的全身环境中不会生长。我们认为，乳腺癌生物学的许多方面只能通过对激活和对系统环境的反应的详细理解来解释。我们建议以以下具体目的基于我们的基本观察。 1。确定哪种类型的乳腺癌能够建立肿瘤支持的全身环境以及如何做到这一点。 2。定义能够对肿瘤促进系统环境做出反应的乳腺癌的特性。 3.确定抑制促进肿瘤环境的某些方面是否会阻止其他惰性肿瘤的生长。 了解某些肿瘤如何激活全身环境应有助于我们设计疗法以抑制其促肿瘤功能。同样重要的是，了解对这些系统性因素反应的肿瘤细胞的特性应该使我们能够确定患者是否具有这些反应性细胞。这些机械研究有可能为更有效的乳腺癌疗法铺平道路。